Picture loading failed.

Anti-PDCD1;CTLA4 therapeutic antibody (Pre-made Cadonilimab biosimilar,Bispecific Mixed mAb and scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cadonilimab (AK104) is a novel, potential next-generation,first-in-classbi-specificPD-1/CTLA-4immuno-oncology backbone drug independently developed by the Company, and its major indications include liver cancer, cervical cancer, lung cancer, gastric cancer, esophageal squamous cell cancer and nasopharyngeal carcinoma.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-088-1mg 1mg 3090
GMP-Bios-ab-088-10mg 10mg 21890
GMP-Bios-ab-088-100mg 100mg 148000
GMP-Bios-ab-088-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-PDCD1;CTLA4 therapeutic antibody (Pre-made Cadonilimab biosimilar,Bispecific Mixed mAb and scFv)
INN Name Cadonilimab
TargetPDCD1;CTLA4
FormatBispecific Mixed mAb and scFv
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1;na
VD LCKappa;Lambda
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2020
Year Recommendedna
CompaniesAkeso Biopharma
Conditions Approvedna
Conditions ActiveNon-small cell lung cancer;Solid tumours;Peripheral T/NK cell lymphoma;Hepatocellular carcinoma;Gastic adenocarcinoma;Nasopharyngeal carcinoma
Conditions Discontinuedna
Development Techna